Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Lipson

Showing results (61-70 of 117) with videos related to

Pageof 12
Sort By:
Respiratory Research|October 29, 2021
Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trialClaus F Vogelmeier, Paul W Jones, Edward M Kerwin, et al.
International Journal of Chronic Obstructive Pulmonary Disease|December 17, 2019
The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese PopulationMotokazu Kato, Keisuke Tomii, Kenichi Hashimoto, et al.
Advances in Therapy|August 4, 2021
Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX TrialLeif H Bjermer, Isabelle H Boucot, Claus F Vogelmeier, et al.
ERJ Open Research|May 12, 2018
Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analysesDavid M G Halpin, Ruby Birk, Noushin Brealey, et al.
Advances in Therapy|November 3, 2017
Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized StudyGregory J Feldman, Ana R Sousa, David A Lipson, et al.
Magnetic Resonance in Medicine|July 6, 2004
Determination of regional VA/Q by hyperpolarized 3He MRIRahim R Rizi, James E Baumgardner, Masaru Ishii, et al.
Respiratory Medicine|August 24, 2021
Genetics plays a limited role in predicting chronic obstructive pulmonary disease treatment response and exacerbationLouise Hosking, Astrid Yeo, Joshua Hoffman, et al.
International Journal of Chronic Obstructive Pulmonary Disease|May 12, 2021
Treatment of COPD with Long-Acting Bronchodilators: Association Between Early and Longer-Term Clinically Important ImprovementClaus F Vogelmeier, Ian P Naya, François Maltais, et al.
Therapeutic Advances in Respiratory Disease|May 29, 2020
Early and sustained symptom improvement with umeclidinium/vilanterol <i>versus</i> monotherapy in COPD: a <i>post hoc</i> analysis of the EMAX randomised controlled trialEdward M Kerwin, Isabelle H Boucot, Claus F Vogelmeier, et al.
International Journal of Chronic Obstructive Pulmonary Disease|July 8, 2021
Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-Naïve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX TrialLeif Bjermer, Isabelle H Boucot, François Maltais, et al.
Pageof 12

Showing results (61-70 of 117) with videos related to

Sort By:
Pageof 12
Respiratory Research|October 29, 2021
Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trialClaus F Vogelmeier, Paul W Jones, Edward M Kerwin, et al.
International Journal of Chronic Obstructive Pulmonary Disease|December 17, 2019
The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese PopulationMotokazu Kato, Keisuke Tomii, Kenichi Hashimoto, et al.
Advances in Therapy|August 4, 2021
Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX TrialLeif H Bjermer, Isabelle H Boucot, Claus F Vogelmeier, et al.
ERJ Open Research|May 12, 2018
Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analysesDavid M G Halpin, Ruby Birk, Noushin Brealey, et al.
Advances in Therapy|November 3, 2017
Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized StudyGregory J Feldman, Ana R Sousa, David A Lipson, et al.
Magnetic Resonance in Medicine|July 6, 2004
Determination of regional VA/Q by hyperpolarized 3He MRIRahim R Rizi, James E Baumgardner, Masaru Ishii, et al.
Respiratory Medicine|August 24, 2021
Genetics plays a limited role in predicting chronic obstructive pulmonary disease treatment response and exacerbationLouise Hosking, Astrid Yeo, Joshua Hoffman, et al.
International Journal of Chronic Obstructive Pulmonary Disease|May 12, 2021
Treatment of COPD with Long-Acting Bronchodilators: Association Between Early and Longer-Term Clinically Important ImprovementClaus F Vogelmeier, Ian P Naya, François Maltais, et al.
Therapeutic Advances in Respiratory Disease|May 29, 2020
Early and sustained symptom improvement with umeclidinium/vilanterol <i>versus</i> monotherapy in COPD: a <i>post hoc</i> analysis of the EMAX randomised controlled trialEdward M Kerwin, Isabelle H Boucot, Claus F Vogelmeier, et al.
International Journal of Chronic Obstructive Pulmonary Disease|July 8, 2021
Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-Naïve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX TrialLeif Bjermer, Isabelle H Boucot, François Maltais, et al.
Pageof 12